228 related articles for article (PubMed ID: 31790905)
1. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
De Ferrari GM; Stevens SR; Ambrosio G; Leonardi S; Armstrong PW; Green JB; Wamil M; Holman RR; Peterson ED;
Am Heart J; 2020 Feb; 220():82-88. PubMed ID: 31790905
[TBL] [Abstract][Full Text] [Related]
2. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
3. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
4. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial.
Giugliano RP; Wiviott SD; Blazing MA; De Ferrari GM; Park JG; Murphy SA; White JA; Tershakovec AM; Cannon CP; Braunwald E
JAMA Cardiol; 2017 May; 2(5):547-555. PubMed ID: 28291866
[TBL] [Abstract][Full Text] [Related]
5. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Pagidipati NJ; Navar AM; Pieper KS; Green JB; Bethel MA; Armstrong PW; Josse RG; McGuire DK; Lokhnygina Y; Cornel JH; Halvorsen S; Strandberg TE; Delibasi T; Holman RR; Peterson ED;
Circulation; 2017 Sep; 136(13):1193-1203. PubMed ID: 28626088
[TBL] [Abstract][Full Text] [Related]
6. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
[TBL] [Abstract][Full Text] [Related]
7. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
8. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
[TBL] [Abstract][Full Text] [Related]
9. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
10. Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes.
Amarenco P; Kim JS; Labreuche J; Charles H; Giroud M; Lee BC; Lavallée PC; Mahagne MH; Meseguer E; Nighoghossian N; Steg PG; Vicaut É; Bruckert E; ;
Diabetes; 2021 Aug; 70(8):1807-1815. PubMed ID: 33980690
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
12. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Brandts J; Tittel SR; Bramlage P; Danne T; Brix JM; Zimny S; Heyer CHJ; Holl RW; Müller-Wieland D
Diabetes Obes Metab; 2023 Dec; 25(12):3700-3708. PubMed ID: 37694759
[TBL] [Abstract][Full Text] [Related]
14. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
[TBL] [Abstract][Full Text] [Related]
15. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
[TBL] [Abstract][Full Text] [Related]
16. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
17. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
Morgan CL; Durand A; McCormack T; Hughes E; Berni TR; Lahoz R
BMJ Open; 2023 Nov; 13(11):e064541. PubMed ID: 38030254
[TBL] [Abstract][Full Text] [Related]
18. Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.
Zhang XL; Lan RF; Zhang XW; Xu W; Wang L; Kang LN; Xu B
J Am Heart Assoc; 2019 Aug; 8(16):e012428. PubMed ID: 31411090
[TBL] [Abstract][Full Text] [Related]
19. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
[TBL] [Abstract][Full Text] [Related]
20. Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Albers JJ; Slee A; Fleg JL; O'Brien KD; Marcovina SM
Atherosclerosis; 2016 Aug; 251():454-459. PubMed ID: 27320173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]